Scilex Holding Company (SCLX)
Scilex Holding Company operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Palo Alto, CA, US. The stock last traded at $6.75, up 0.66% on the session, giving a market capitalisation of $57.4M. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of -1239.4%. Its beta of 1.74 implies it has historically moved more than the broad market.
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Scilex Holding Company is most often compared with the following Healthcare names: